Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers

This study has been completed.

Sponsor:

Collaborators:

Radboud University

Biomedical Primate Research Centre

GlaxoSmithKline

SEPPIC, Paris

Information provided by:

European Malaria Vaccine Initiative

ClinicalTrials.gov Identifier:

NCT00730782

First received: August 6, 2008

Last updated: August 7, 2008

Last verified: August 2008

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	August 2008
Primary Completion Date:	September 2007 (Final data collection date for primary outcome measure)

No publications provided by European Malaria Vaccine Initiative

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Remarque EJ, Roestenberg M, Younis S, Walraven V, van der Werff N, Faber BW, Leroy O, Sauerwein R, Kocken CH, Thomas AW. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults. PLoS One. 2012;7(6):e38898. Epub 2012 Jun 29.

Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE. 2008;3(12):e3960. Epub 2008 Dec 18.

To Top